INTRODUCTION {#s1}
============

Viral respiratory infections are the main causes of asthma exacerbations in both adults and children. Coronaviruses are commonly isolated in the respiratory tract of these patients \[[@C1]\]. As the world faces the coronavirus disease 2019 (COVID-19) pandemic due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, concerns have arisen about a possible increased risk of asthma exacerbations. Indeed, SARS-CoV-2 is well known for its respiratory tropism that can lead to severe pneumonia and potentially fatal acute respiratory distress syndrome (ARDS) \[[@C2]\]. However, the prevalence of asthma among inpatients with COVID-19 remains debated. In Wuhan, authors pointed out a rate of 0.9% \[[@C3]\], markedly lower than that in the local population; in another study investigating the clinical characteristics and allergy status of 140 patients infected by SARS-CoV-2 in Wuhan, no patient were reported as being asthmatic \[[@C3]\]. Conversely, other authors found that asthmatics accounted for 12.5% of total COVID-19 inpatients in New York \[[@C4]\]. Beside those conflicting statistics, the characteristics and the outcomes of asthmatic patients infected with SARS-CoV-2 have not yet been described in detail.

In France, the Great Paris region (*Ile-de-France*) has been particularly affected by the epidemic. On March 14, 2020, the Regional Health Agency issued a statement underscoring the rapid spread of SARS-CoV-2 in the region with 376 new daily confirmed cases \[[@C5]\]; the number of regional hospitalisations for COVID-19 eventually reached a peak on April 1st \[[@C6]\]. From March 15, 2020 to April 15, 2020 we carried out a prospective study in Bicêtre Hospital, University Paris-Saclay, France. The objective of this study was to investigate the characteristics and outcomes of asthmatic patients with COVID-19 pneumonia who required hospitalisation.

MATERIAL AND METHODS {#s2}
====================

Patients and study design {#s2a}
-------------------------

A prospective monocentric cohort follow-up was initiated in Bicêtre Hospital, France. All adult patients hospitalised from March 15, 2020 to April 15, 2020 with a diagnosis of SARS-CoV-2 infection and reporting a history of asthma were included. Decision of hospitalisation was based on a concerted decision algorithm that has been locally implemented into clinical practice during the French COVID-19 outbreak ([supplementary Figure 1](http://erj.ersjournals.com/lookup/doi/10.1183/13993003.01875-2020.figures-only#fig-data-supplementary-materials)). COVID-19 was first suspected on the basis of compatible symptoms: in suspected cases, both SARS-CoV-2 reverse transcription polymerase chain reaction (RT-PCR) on nasopharyngeal swab and computed tomography (CT) of the chest were systematically performed. Diagnosis was confirmed in the presence of positive SARS-CoV-2 RT-PCR and/or typical CT abnormalities (*i.e.* ground-glass opacities and/or consolidation in the lung periphery) \[[@C7]\]. A random control group of 75 non-asthmatic patients hospitalised for COVID-19 pneumonia in our hospital during the same period has been included and analysed. Patients received written information about data collection. After inclusion, all data regarding the clinical status, main outcomes, biological and radiological features were recorded in an anymous database registred to the National Commission on Informatics and Liberty (n° 2217978).

![Blood lymphocyte (a) and eosinophil (b) count at admission.](ERJ-01875-2020.01){#F1}

Characteristics at diagnosis and outcomes {#s2b}
-----------------------------------------

The following data were collected after patient-centered interviews: comorbid conditions (obesity, hypertension, diabetes, renal failure, coronary heart disease); current smoking status ("non-smokers" referring to both former and never smokers); history of asthma; asthma controller treatment with classification from step 1 to 5 according to the last 2020 Global Initiative for Asthma (GINA) report \[[@C8]\]; when feasable, we also clarified with the patient or his family whether asthma diagnosis had been confirmed by a pulmonologist or not. In addition, the following laboratory tests were analysed at admission: SARS-CoV-2 RT-PCR result, blood count, cardiac biomarkers, liver function, arterial blood gas, C-reactive protein (CRP), fibrinogen, D-dimers, creatine phosphokinase (CPK), lactate dehydrogenase (LDH), ferritin. CT of the chest was analysed by a radiologist and a pulmonologist and the extent of lesions was classified as mild (\<10%), moderate (10--24%), severe (25--49%), very severe (50--74%), and critical (≥ 75%). The following management strategies were detailed: use of systemic corticosteroids (CS), short-acting beta-agonists (SABA), antibiotics, adjustement of asthma controller, oxygen flow, intensive care unit (ICU) admission, and mechanical ventilation requirement. Finally, the main outcomes (mortality, length of ICU stay and total length of hospital stay) were investigated after a one-month follow-up.

Statistical methods {#s2c}
-------------------

Quantitative data were expressed as median (interquartile range) (IQR, presented as first quartile -- third quartile). Qualitative data were expressed as number of occurrence, n (%). In case of missing data, the number of patients with available informations was provided next to each variable. When this number was not specified, data of entire population was available and analysed. Student\'s *t*-test or Mann-Whitney U test (if not normally distributed) were used to compare the continuous variables between two groups. Pearson\'s chi-square (χ2) test or Fisher\'s exact tests if appropriate, were used to compare discrete variables between two groups.

RESULTS {#s3}
=======

Clinical characteristics of patients hospitalised for COVID-19 pneumonia {#s3a}
------------------------------------------------------------------------

Among 768 hospitalised COVID-19 patients, 37 (4.8%) reported a history of asthma. Thirty-one asthmatics had positive SARS-CoV-2 RT-PCR on nasopharyngeal swab (84%). The remaining six were diagnosed on the basis of clinical presentation and radiological patterns \[[@C7]\].

Asthmatic patients were mainly female (70%), non-smokers (85%), with a median age of 54 years (42--67) and a median body mass index (BMI) of 28.3 kg·m^−2^ (26.8--31.5). In 85% of cases the diagnosis of asthma had been previously confirmed by a pulmonologist. Eleven patients (30%) were GINA step 5, receiving high doses inhaled CS (ICS) with long-acting-beta agonists (LABA), associated with low dose oral CS in one case, and long-term omalizumab therapy in two ([Supplementary Table 1](http://erj.ersjournals.com/lookup/doi/10.1183/13993003.01875-2020.figures-only#fig-data-supplementary-materials)).Thirty-one asthmatics (84%) had a BMI ≥25 kg·m^−2^. Twenty-two (59%) had at least one major comorbidity. The most common comorbid conditions were obesity (36%), hypertension (27%) and diabetes (19%). Fifteen (41%) had multimorbidities ([table 1](#TB1){ref-type="table"}).

###### 

Patients characteristics and medical history at inclusion

  **Patients characteristics**       **Asthmatics (n=37)**   **Controls (n=75)**     **p-value**
  ---------------------------------- ----------------------- ----------------------- -------------
  **Age (years)**                    54 (42--67)             60 (52--70)             **0.019**
  **Gender, male/female**            11 (30)/26 (70)         49 (65)/26 (35)         **\<0.001**
  **BMI (kg·m^−2^)**                 28.3 (26.8--31.5)       28.7 (26.8--31.2)^\#^   0.856
  **Tobacco exposure:**                                                              
   Current/former smokers            12 (32)                 18 (24)                 0.343
   Never smokers                     25 (68)                 57 (76)                 0.343
  **Comorbid conditions**                                                            
  **1. Obesity**                     13 (36)                 24/65 (37)              0.901
   Class I (30 ≤BMI \<35)            5                       17                      
   Class II (35 ≤BMI \<40)           6                       4                       
   Class III (BMI ≥40)               2                       3                       0.613
  **2. Overweight (25 ≤BMI \<30)**   18 (49)                 35/65 (54)              0.161
  **3. Hypertension**                10 (27)                 32 (43)                 0.834
  **4. Diabetes**                    7 (19)                  17 (23)                 1.000
  **5. Renal failure**               3 (8)                   6 (8)                   
   Dialysis                          2                       3                       
   Nephrectomy                       1                       0                       1.000
  **6. Coronary heart disease**      2 (5)                   6 (8)                   0.253
  **At least two of the six**        15 (41)                 35/67 (52)              

Quantitative data are expressed as median (IQR). IQR is presented as first quartile (Q1) -- third quartile (Q3). Qualitative data are expressed as number of occurrence, n (% of total). In case of variable with missing data, the number of patients with available information is specified. BMI: body mass index; GINA step refers to the treatment strategy proposed in the 2020 Global Initiative for Asthma report \[8\]; IQR: interquartile range.

^\#^65 available data.

The median time from onset of symptoms to admission in the emergency room was 6 days (3--8). Fifty percent of patients had an initial peripheral oxygen saturation below 95% while breathing room air and 25% had a respiratory rate above 30/min. None of them presented with an asthma exacerbation. Wheezing, mostly reported as mild, was reported at admission in only 6 cases (16%) ([table 2](#TB2){ref-type="table"}).

###### 

Clinical features at presentation in the emergency room

  **Variable**                            **Asthmatics (n=37)**   **Controls (n=75)**   **p-value**   ***Available data* n *(asthmatics, controls)***
  --------------------------------------- ----------------------- --------------------- ------------- -------------------------------------------------
  **Time since onset of symptoms days**   6 (3--8)                7 (3--10)             0.239         *37, 75*
  **Systolic blood pressure mmHg**        132 (123--145)          138 (122--151)        0.457         *36, 73*
  **Diastolic blood pressure mmHg**       81 (71--89)             79 (69--88)           0.993         *36, 73*
  **Heart rate min^−1^**                  99 (88--111)            100 (89--109)         0.714         *36, 73*
  **Temperature C**                       38.1 (37.3--38.7)       38.2 (27.4--38.7)     0.899         *36, 74*
  **Respiratory rate min^−1^**            26 (20--30)             28 (20--32)           0.361         *31, 62*
  **SpO~2~ while breathing room air %**   95 (92--97)             93 (89--95)           **0.008**     *35, 71*
  **Wheezing**                            6 (16)                  2 (3)                 **0.015**     *37, 75*
   Mild wheezing                          5                       0                                   *37, 75*
   Severe wheezing                        1                       2                                   *37, 75*

Quantitative data are expressed as median (IQR). IQR is presented as first quartile (Q1) -- third quartile (Q3). Qualitative data are expressed as number of occurrence, n (% of total). IQR: interquartile range; SpO~2~: oxygen peripheral saturation.

Non-asthmatic controls are presented in [tables 1](#TB1){ref-type="table"} and [2](#TB2){ref-type="table"}. All differences pointed to worst COVID-19 pneumonia in non-asthmatics, as evidenced by older age, higher male/female gender rate, and a trend to more comorbidities.

Biological findings at inclusion {#s3b}
--------------------------------

Laboratory values in the emergency room are summarised in [table 3](#TB3){ref-type="table"}. Among asthmatics, lymphopenia was a frequent finding (median 1205/mm3, IQR 738--1476) ([fig. 1a](#F1){ref-type="fig"}). Patients also presented with a marked eosinopenia, 78% having a blood eosinophils count equal to zero ([fig. 1b](#F1){ref-type="fig"}). N-terminal pro--B-type natriuretic peptide (NT-pro BNP) was measured in 21 patients and normal value (\<300 ng·L^−1^) was found in 81% of cases. Of 31 available data, 6 patients (19%) had increased high-sensitive cardiac troponin T (≥14 ng·L^−1^); however, none of these patients demonstrated consistent evidence of serious myocardial injury. Elevation of D-dimers was commonly observed (median 810 µg·L^−1^, IQR 483--1180), as well as increased CRP levels (median CRP 51 mg·L^−1^, IQR 27--116). Arterial blood gas while breathing room air was available in 29 patients : hypoxaemia was a common finding (median arterial partial pressure of oxygen (PaO~2~) 68 mmHg, IQR 62--83) with hypocapnia (median arterial partial pressure of carbon dioxide (PaCO~2~) 34 mmHg, IQR 32--38).

###### 

Laboratory results at diagnosis

  **Variable**                   **Asthmatics (n=37)**        **Controls (n=75)**          **p-value**   ***Available data* n *(asthmatics, controls)***
  ------------------------------ ---------------------------- ---------------------------- ------------- -------------------------------------------------
  **Leucocytes mm^−3^**          6990 (5710--9020)            6690 (5330--9483)            0.719         *37, 74*
  **Haemoglobin g·dL^−1^**       13.0 (12.3--14.7)            13.5 (12.6--14.6)            0.819         *37, 74*
  **Platelets mm^−3^**           213 000 (159 000--239 000)   206 000 (165 000--254 000)   0.699         *37, 74*
  **Neutrophils mm^−3^**         5225 (2835--6910)            5160 (3815--7698)            0.883         *36, 74*
  **Eosinophils mm^−3^**         0 (0--0)                     0 (0--0)                     0.254         *36, 74*
  **Lymphocytes mm^−3^**         1205 (738--1475)             890 (623--1308)              0.151         *36, 74*
  **Fibrinogen g·L^−1^**         5.2 (4.2--6.2)               6.1 (5.1--7.2)               **0.002**     *35, 73*
  **D-dimers μg·L^−1^**          810 (483--1180)              1080 (680--1508)             0.329         *34, 64*
  **CRP mg·L^−1^**               51 (27--116)                 86 (51--174)                 **0.040**     *37, 75*
  **LDH UI/L**                   283 (235--359)               392 (311--512)               **0.005**     *31, 66*
  **CPK UI/L**                   100 (62--160)                189 (84--390)                0.245         *33, 71*
  **ASAT UI/L**                  38 (25--62)                  51 (39--73)                  **0.022**     *33, 69*
  **ALAT UI/L**                  30 (23--47)                  37 (27--64)                  0.058         *34, 71*
  **Bilirubin mg·L^−1^**         6 (4--8)                     9 (6--13)                    0.157         *34, 71*
  **Troponin T HS ng·L^−1^**     6 (4--13)                    12 (8--21)                   0.119         *31, 63*
  **NT-pro BNP ng·L^−1^**        131 (52--214)                230 (54--1713)               0.745         *21, 44*
  **Ferritin ng·mL^−1^**         632 (460--985)               1626 (903--3031)             **0.034**     *8, 15*
  **PaO~2~ in room air mmHg**    68 (62--83)                  63 (52--74)                  **0.010**     *29, 61*
  **PaCO~2~ in room air mmHg**   34 (32--38)                  35 (32--38)                  0.762         *29, 61*

Data are expressed as median (IQR). IQR is presented as first quartile (Q1) -- third quartile (Q3).

ALAT: alanine aminotransferase; ASAT: aspartate transaminase; CPK: creatine phosphokinase; CRP: C-Reactive Protein; IQR: interquartile range; LDH: lactate dehydrogenase; Nt-pro BNP: N-terminal pro--B-type natriuretic peptide; PaCO2: arterial partial pressure of carbon dioxide; PaO2: arterial partial pressure of oxygen; Troponin T HS: high-sensitive cardiac troponin T.

Non-asthmatic controls are presented in [table 3](#TB3){ref-type="table"}. There was a trend for more pronounced lymphopenia and worst CRP, D-dimers, LDH, liver transaminases levels, with more severe hypoxemia.

Radiological findings {#s3c}
---------------------

All asthmatics underwent a CT of the chest ([table 4](#TB4){ref-type="table"}). Peripheral or mixed ground glass opacities were the most frequent CT patterns (95% of cases), expanding over more than 10 percent of lung parenchyma in 76% of cases. Consolidations were observed in 26 patients (70%) and crazy-paving pattern in 13 patients (35%). In 51% of cases, lesions predominated in inferior lobes. Based on clinical judgement or prediction rules \[[@C9]\], four patients had initial CT pulmonary angiography (CTPA), demonstrating two cases of acute pulmonary embolisms (PE) at admission. Eight additional CTPA were performed during hospital stays for clinical deterioration, leading to another acute PE diagnosis. In this small cohort of patients, higher inhaled corticosteroid exposure was not associated with higher proportion of severe radiological pneumonia; mild pneumonia tended to be more frequent in asthmatics with higher doses of ICS ([Supplementary Figure 2](http://erj.ersjournals.com/lookup/doi/10.1183/13993003.01875-2020.figures-only#fig-data-supplementary-materials)).

###### 

Computed of the chest features of COVID-19 pneumonia

  **Variable**                   **Asthmatics (n=37)**   **Controls (n=75)^\#^**   **p-value**
  ------------------------------ ----------------------- ------------------------- -------------
  **Ground glass opacities**     36 (97)                 64 (97)                   1.000
  **Consolidations**             26 (70)                 56 (85)                   0.132
  **Lower lobes predominance**   19 (51)                 44 (67)                   0.187
  **Crazy paving**               13 (38)                 30 (45)                   0.453
  **Topography**                                                                   
   Peripheral                    22 (59)                 39 (59)                   0.971
   Central                       1 (3)                   1 (2)                     1.000
   Mixed                         14 (38)                 26 (39)                   0.876
  **Lesion extent**                                                                
   Mild (\<10%)                  9 (24)                  6 (9)                     **0.035**
   Moderate (10--25%)            15 (41)                 18 (27)                   0.166
   Severe (25--50%)              11 (30)                 31 (47)                   0.088
   Very severe (50--75%)         1 (3)                   10 (16)                   **0.050**
   Critical (\>75%)              1 (3)                   1 (1)                     1.000
   Mild-to-moderate              24 (65)                 24 (36)                   **0.005**
   Severe-to-critical            13 (35)                 42 (64)                   **0.005**

Data are expressed as number of occurrence, n (% of total).

^\#^66 available data.

###### 

Outcomes of patients with COVID-19 pneumonia.

![](ERJ-01875-2020.02a)
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All non-asthmatic controls had imaging of the chest at admission (66 CT and 9 chest X ray). The results of CT of the chest are presented in [table 4](#TB4){ref-type="table"}. As compared to asthmatics, there was more sereve-to-critical radiological presentation in the non-asthmatics.

Management and outcomes {#s3d}
-----------------------

As shown in [table 5](#TB5){ref-type="table"}, 30 (81%) asthmatics received oxygen with use of high-concentration masks in 10 patients. When nasal oxygen was used, the median oxygen flow-rate was 2 L·min^−1^. In two patients, oxygen had to be maintained after discharge. Thirty-one (84%) received at least one antibiotic. SABA as needed was prescribed using a pressurised metered-dose inhaler (p-MDI) with a spacer chamber and previous inhaled treatments were maintained. Five patients received oral CS before admission, one of them in the context of self-medication. Three additional patients received intravenous CS during hospital stay: refractory ARDS was the main cause of CS prescription in two cases and bronchospasm occurring in the context of mechanical ventilation in one case. Eleven patients were admitted in ICU, six of them requiring invasive mechanical ventilation. There was a trend for more aged and comorbid patients among patients admitted in ICU ([table 6](#TB6){ref-type="table"}). A flowchart of the main outcomes is presented in [figure 2](#F2){ref-type="fig"}. As shown in [figure 3](#F3){ref-type="fig"}, asthmatics without multimorbidities were discharged at home earlier.

###### 

Management of asthmatic patients with COVID-19

  **Management**                                                     
  ------------------------------------------------------------------ ------------
  **Oxygen**                                                         30 (81)
  **Antibiotic(s)**                                                  31 (84)
   Azithromycin                                                      16 (52)
  **IV or oral CS for asthma exacerbation during hospitalisation**   1 (3)
  **SABA prescription**                                              31/36 (86)
   pMDI+spacer chamber                                               29/31 (94)
   DPI                                                               2/31 (6)
   Nebulized                                                         4/31 (13)
  **Asthma controller treatment adjustment**                         
   Maintenance                                                       33/35 (94)
   Stepped-up                                                        1/35 (3)

Quantitative data are expressed as median (IQR). IQR is presented as first quartile (Q1) -- third quartile (Q3). Qualitative data are expressed as number of occurrences, n (% of total). In case of variable with missing data, the number of patients with available information is specified.

###### 

Description of asthmatics admitted or not in ICU

  **Patients characteristics**     **ICU (n=11)**   **No ICU (n=26)**   **p value**
  -------------------------------- ---------------- ------------------- -------------
  **Age (years)**                  61 (50--68)      50 (41--61)         0.162
  **Gender, male/female**          4 (26)/7 (64)    7 (17)/19 (73)      0.699
  **BMI (kg·m^−2^)**               29 (28--32)      28 (25--31)         0.144
  **Tobacco exposure:**                                                 
   Current/former smokers          3 (27)           9 (35)              1.000
   Never smokers                   8 (73)           17 (65)             1.000
  **Asthma management**                                                 
  **No ICS**                       2 (18)           10 (38)             0.279
  **Low/medium dose ICS**          4 (36)           10 (38)             1.000
  **High dose ICS**                5 (45)           6 (24)              0.244
   Biologic therapy (omalizumab)   1 (9)            1 (4)               
   Oral corticosteroids            1 (9)            0 (0)               
  **Comorbid conditions**                                               
  Obesity (BMI ≥30)                5 (45)           8 (31)              0.465
  Overweight (25 ≤BMI \<30)        6 (55)           12 (46)             0.728
  Hypertension                     6 (55)           5 (19)              0.051
  Diabetes                         1 (9)            6 (32)              0.649
  Renal failure                    1 (9)            2 (8)               1.000
  Coronary heart disease           0 (0)            2 (8)               1.000
  **At least two of the six**      7 (64)           8 (31)              0.080

Quantitative data are expressed as median (IQR). IQR is presented as first quartile (Q1) -- third quartile (Q3). Qualitative data are expressed as number of occurrences, n (% of total).

BMI: body mass index; ICS: inhaled corticosteroids; ICU: intensive care unit.

![Proportion of asthmatics discharged at home at 30 days according to the number of their comorbidities.](ERJ-01875-2020.03){#F3}

CS: corticosteroids; DPI: dry powder inhaler; IQR: interquartile range; IV: intravenous; pMDI: pressurised metered-dose inhaler; SABA: short-acting bronchodilators.

Two deaths occurred at one-month follow-up and one additional death was later noted, thus leading to a mortality rate of 8.1% in asthmatics (as compared to 14.6% in non-asthmatics, p=0.381). The first patient was a 68 year-old woman treated for asthma by her pulmonologist with fluticasone/salmeterol 500/50 µg daily (medium doses, GINA step 4). She had several comorbidities including obesity (BMI=31.2 kg·m^−2^), diabetes, current chemotherapy for ovarian cancer, dyslipidemia and sleep apnea syndrome. At admission, no wheezing was reported, she was eosinopenic (0/mm^3^), had positive nasal SARS-CoV-2 RT-PCR and presented with mild extent of pulmonary lesions on CT of the chest. 5 days after symptoms had started, she was transfered in ICU for acute respiratory failure. No acute PE was detected on CTPA. Due do an extremely poor prognosis, it was decided to restrict advanced life support, including intubation. She died on day 9. The second patient was a 67 year-old woman with a diagnosis of asthma confirmed by a pulmonologist and treated with inhaled beclometasone/formoterol 200/12 µg daily (low doses, GINA step 3). She also displayed severe obesity (BMI=43 kg·m^−2^), hypertension, renal failure requiring chronic dialysis and primary biliary cirrhosis. Mild wheezing was noted at admission along with positive nasal SARS-CoV-2 RT-PCR, eosinopenia (0/mm^3^) and severe extent of pulmonary lesions on CT of the chest. 10 days after symptoms had started, she was intubated in ICU for acute respiratory failure. She died at day 15 from refractory ARDS. The third patient was a 75 year-old hypertensive and overweight woman (BMI=29.4) treated for asthma with budesonide/formoterol 1200/36 µg daily (high doses, GINA step 5). At admission in the emergency room, no wheezing was reported; she was eosinopenic (0/mm^3^), had positive nasal SARS-CoV-2 RT-PCR and presented with very severe extent of radiological lesions (50--75%). She was intubated 4 days later. Bronchospasm occurred during mechanical ventilation and systemic corticosteroids were administrated at day 12. Withdrawal of mechanical ventilation was not possible: she died at day 45 from respiratory failure.

Evolution of asthmatics treated with biologics {#s3e}
----------------------------------------------

Two patients were treated with anti-immunoglobulin E monoclonal antibody (omalizumab) for severe allergic asthma. The first one was a 53 year-old woman treated with budesonide/formoterol 800/12 µg daily, montelukast 10 mg·j^−1^ and subcutaneous omalizumab at a monthly dose of 300 mg. She had no sign of asthma exacerbation before admission, but took a short course of oral prednisone (40 mg·day^−1^) during 5 days as self medication that was stopped at admission. She had positive nasal SARS-CoV-2 RT-PCR, eosinopenia (0/mm^3^) and a moderate extent of lesions on CT of the chest. She had no evidence of asthma exacerbation nor respiratory failure, allowing discharge at home on day 5.

The second patient was a 78 year-old overweight woman with severe allergic asthma and allergic bronchopulmonary aspergillosis, treated with budesonide/formoterol 800/12 µg daily, oral prednisone 5 mg·j^−1^ and subcutaneous omalizumab 300 mg twice monthly. She also suffered from hypothyroidism, lumbar spinal stenosis and depression. Initial presentation included crackles and minor wheezing, with positive nasal SARS-CoV-2 RT-PCR, blood eosinophil count of 50/mm^3^ and severe extent of pneumonia on CT at admission ([fig. 4a](#F4){ref-type="fig"}). 9 days after the beginning of symptoms, she was admitted in ICU for acute respiratory failure. Oro-tracheal intubation was needed and mechanical ventilation was well tolerated with no evidence of bronchospasm. After 8 days of mechanical ventilation, acute bronchospasm appeared for the first time. *Aspergillus fumigatus* was detected in bronchial secretions. Segmental acute PE was diagnosed 12 days after admission ([fig. 4b](#F4){ref-type="fig"}). Other treatments included anticoagulation, bronchodilator nebulizations, intravenous CS and voriconazole. The next omalizumab injection has been administrated as planned, when she was under mechanical ventilation. No adverse events were observed and successful extubation was possible 5 days later. She was discharged of ICU after 23 days. At day 75, she was well and alive, still undergoing rehabilitation.

![Computed tomography of the chest of the same patient with severe allergic asthma at day 1 (a) and day 12 (b) of hospitalisation. a) Typical extended ground glass opacities with crazy-paving pattern (solid arrow) and nodular consolidations (dashed arrow). b) Computed tomography with pulmonary angiography revealing acute pulmonary embolism in the right lower lobe pulmonary artery (white arrow).](ERJ-01875-2020.04){#F4}

DISCUSSION {#s4}
==========

This prospective monocentric cohort describes clinical, biological and radiological characteristics and outcomes of asthmatics with COVID-19 pneumonia who require hospitalisation. During the spring 2020 outbreak, asthmatics accounted for less than 5% of total hospitalised patients in our institution. The most recent data available in France indicate that 6.4% of individuals have a current diagnosis of asthma \[[@C10]\]. In line with previous reports \[[@C11]\], our results suggest that asthmatics were thus not over-represented among COVID-19 inpatients. In addition, no patient was hospitalised for a COVID-19 related asthma exacerbation during the outbreak and very few developed an asthma attack while hospitalised, which is consistent with data recently reported in Strasbourg, France \[[@C12]\]. This contrasts sharply with viral respiratory infections, including other types of coronavirus, being the main causes of asthma exacerbations \[[@C1]\].

Several mechanisms may explain this apparent paradox. First, a lower expression of SARS-CoV-2 cellular receptor angiotensin-converting enzyme-2 (ACE2) has been described in airways cells of patients with respiratory allergy and/or asthma, and it was also found that ACE2 expression was inversely associated with type 2 biomarkers \[[@C13]\]. Of note, severe eosinopenia was a typical biologic feature in our cohort, 78% of hospitalised asthmatics having no detectable blood eosinophils at admission. This finding is unusual in hospitalised asthmatics receiving neither systemic CS nor anti-interleukin 5 (IL-5) therapy. Similar findings were reported in a mostly non-asthmatic COVID-19 population in Wuhan, China, where eosinopenia was described in 53% of hospitalised subjects \[[@C14]\] and in 81% of fatal cases \[[@C15]\]. As suggested by others \[[@C16]\], eosinopenia in COVID-19 may be a marker of more severe disease. In addition, one may speculate that it reflects a down-regulation of type 2 inflammation that might decrease the risk of asthma exacerbation orchestrated by type 2 responses. Of note, it has been recently showed that severe COVID-19 is driven by inappropriate inflammatory response defined by low levels of type I and III interferons juxtaposed to elevated chemokines and high expression of IL-6, supporting the concept that reduced innate antiviral defenses coupled with exuberant proinflammatory cytokine production are the defining and driving features of COVID-19 \[[@C17]\]. Further studies are needed, describing the cytokine profile of asthmatics in response to SARS-CoV-2 infection. Furthermore, there is *in vitro* evidence to support a protective effect of ICS on coronaviruses infections \[[@C18]\]. Indeed, sputum analysis showed that ACE2 expression levels are significantly lower in asthma patients taking ICS than in those not taking ICS, especially when high doses are administrated \[[@C19]\]. Randomised control trials are needed to test the effect of ICS on COVID-19 in both asthmatics and non-asthmatics patients.

We observed a female predominance (70%) in our cohort, whereas previous works demonstrated an increased risk of SARS-CoV-2 infection in males \[[@C20]\]. This might be explained by age-related sex ratio differences, asthma being more prevalent in female adults \[[@C21], [@C22]\]. Moreover, obesity, hypertension and diabetes were the most common comorbidities observed in our cohort of hospitalised asthmatics with COVID-19, which is consistent with earlier research in other patient groups \[[@C4], [@C23]\]. Interestingly, obesity has been associated with asthma in women \[[@C24]\] and severe forms of COVID-19 in both genders \[[@C25], [@C26]\].

Asthmatic patients with COVID-19 pneumonia who required hospitalisation presented with radiological characteristics similar to those described previously, with a predominance of peripheral ground glass opacities \[[@C27]\]. Interestingly, three patients had a diagnosis of acute PE (8.1%) on CTPA at admission or during hospitalisation. At the start of the COVID-19 outbreak, the first-line imaging tool in our centre relied on non-contrast CT of the chest \[[@C7]\]. However, more concern has been recently raised about thrombosis and pulmonary embolism in COVID-19 patients \[[@C28]\], underscoring that this complication may be more prevalent in this patient population.

Asthma therapy was unchanged in all patients, including biologics, as recommended by the French Asthma and Allergy Working Group (G2A) \[[@C29]\]. Interestingly, two patients were on omalizumab therapy prior to COVID-19. In one patient, the planned omalizumab injection has been administrated while she was under mechanical ventilation, experiencing severe bronchospasm and ARDS. No adverse events were observed and successful extubation was possible 5 days later.

Our study included a control group of COVID-19 pneumonia hospitalised in the same hospital during the same period. As compared to controls, asthmatics were younger, more likely to be female and they tended to be less comorbid, which may explain at least in part, the better outcomes in this population. However, it is interesting to note that mild pneumonia tended to be more frequent in asthmatics with higher doses of ICS ([supplementary Figure 2](http://erj.ersjournals.com/lookup/doi/10.1183/13993003.01875-2020.figures-only#fig-data-supplementary-materials)). Further studies are needed to investigate the possible positive effect of inhaled corticosteroids on COVID-19 pneumonia as previously showed with dexamethasone in the RECOVERY trial \[[@C30]\]. The ongoing INHASCO trial (NCT04331054) is investigating this research question.

One of the study limitations is the relative small number of asthmatic patients being investigated. However, all patients were identified prospectively by an expert team of asthma specialists in a large University hospital hosting a severe asthma clinic, allowing systematic analysis of relevant information and meticulous follow-up. In a state of emergency, misdiagnoses of both asthma and COVID-19 cannot be excluded. Regarding asthma, it could be underdiagnosed, as diagnosis was based on self-report and pulmonary function tests could not be performed during the outbreak. Asthma might also be overdiagnosed, as previously reported in industrialised countries especially in obese individuals \[[@C31]\]. Nevertheless, asthma diagnosis had been previously confirmed by a pulmonologist in 85% of cases. A COVID-19 overdiagnosis is also unlikely, with positive SARS-CoV-2 RT-PCR on nasopharyngeal swab in 84% of cases. RT-PCR was negative in only six patients who presented with a high clinical suspiscion of COVID-19 and consistent CT of the chest during the outbreak \[[@C7]\].

In conclusion, our data indicate that asthmatics were not over-represented in a large group of hospitalised pneumonia during the spring 2020 COVID-19 outbreak in Paris, France. In addition, COVID-19 pneumonia was not associated with asthma exacerbation at admission and at one-month follow-up in patients who did not modify their asthma treatment including GINA step 5 (high doses ICS with LABA, low dose oral CS, and long-term omalizumab). Large multicenter cohort studies are needed to confirm these data and explore the reasons why SARS-CoV-2 does not seem to trigger as many asthma exacerbations, as previously seen with other respiratory viruses.
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